Acasă › Cancer pulmonar cu celule non-pătrate › California › Mountain View
Studii clinice pentru Cancer pulmonar cu celule non-pătrate în Mountain View, CA
21 studii pentru Cancer pulmonar cu celule non-pătrate caută participanți în și în jurul orașului Mountain View (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · La 5 mi distanță
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
În curs de recrutareFaza 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · La 5 mi distanță
- Stanford Cancer Institute Palo Alto, Palo Alto · La 5 mi distanță
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
În curs de recrutareFaza 3
- Stanford University, Stanford · La 5 mi distanță
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
În curs de recrutareFaza 2
- Stanford Cancer Institute, Stanford · La 5 mi distanță
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
În curs de recrutareStudiu observațional
- Stanford University, Palo Alto · La 5 mi distanță
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
În curs de recrutareFaza 2
- Stanford Cancer Institute, Stanford · La 5 mi distanță
- Stanford Hospital and Clinics, Stanford · La 5 mi distanță
- Stanford Hospital Investigational Drug Services, Stanford · La 5 mi distanță
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
În curs de recrutareFaza 3
- Stanford Cancer Center, Palo Alto · La 5 mi distanță
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
În curs de recrutareFaza 1/2
- Stanford Cancer Institute, Stanford · La 5 mi distanță
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
În curs de recrutareFaza 1/2
- Stanford University Medical Center - Neurology, Stanford · La 5 mi distanță
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
În curs de recrutareFaza 3
- Palo Alto Medical Foundation Research Center, Palo Alto · La 5 mi distanță
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
În curs de recrutareFaza 1/2
- Stanford Cancer Institute, Stanford · La 5 mi distanță
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
În curs de recrutareFaza 1/2
- Stanford University Medical Center, Stanford · La 5 mi distanță
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
În curs de recrutareFaza 1
- Stanford University Medical Center, Palo Alto · La 5 mi distanță
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
În curs de recrutareFaza 1
- Stanford University, Palo Alto · La 5 mi distanță
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
În curs de recrutareFaza 1/2
- Stanford University - Stanford Cancer Institute, Stanford · La 5 mi distanță
A Study of LY4175408 in Participants With Advanced Cancer
În curs de recrutareFaza 1
- Stanford Medicine Cancer Center, Stanford · La 5 mi distanță
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
În curs de recrutareFaza 1/2
- Stanford University, Stanford · La 5 mi distanță
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
În curs de recrutareFaza 1/2
- Stanford Women's Cancer Center, Palo Alto · La 5 mi distanță
Engagement of Veterans With Lung Cancer
În curs de recrutare
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · La 5 mi distanță
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Stanford · La 5 mi distanță
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
În curs de recrutareFaza 1
- Stanford University, Stanford · La 5 mi distanță
Studii pentru Cancer pulmonar cu celule non-pătrate în alte orașe
- Houston, TX145 studii
- New York City, NY121 studii
- Arlington, VA104 studii
- Nashville, TN97 studii
- Boston, MA90 studii
- Los Angeles, CA87 studii
- St. Louis, MO73 studii
- Chicago, IL61 studii
- Baltimore, MD60 studii
- San Antonio, TX59 studii
- Columbus, OH57 studii
- Washington, DC55 studii
Alte studii în Mountain View
- Cancer (toate tipurile)40 studii
- Cancer de sân26 studii
- Cancer metastatic25 studii
- Leucemie mieloasă acută19 studii
- Cancer ovarian19 studii
- Tulburare din spectrul autist17 studii
- Cancer pulmonar17 studii
- Cancer de prostată15 studii
- Insuficiență cardiacă15 studii
- Autism13 studii
- Leucemie limfoblastică acută13 studii
- Cancer colorectal13 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.